Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial.
NPJ Breast Cancer
; 9(1): 6, 2023 Feb 04.
Article
in En
| MEDLINE
| ID: mdl-36739285
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
NPJ Breast Cancer
Year:
2023
Document type:
Article
Affiliation country:
Italy